Related Experiment Video
Updated: Aug 5, 2026
Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
Published on: April 24, 2016
Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary
Satoshi Kano1, Daisuke Kawakita2, Yoshitaka Honma3
1Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Background:
Optimal treatment for non-metastatic unresectable salivary duct carcinoma (SDC) remains unclear. We compared outcomes of upfront biomarker-targeted systemic therapy and radiotherapy.
Methods:
We retrospectively analyzed the Joint SDC Study Group registry. Thirty-one patients with centrally confirmed non-metastatic unresectable SDC were classified by initial treatment (radiotherapy or systemic therapy). Systemic therapy included trastuzumab plus docetaxel, combined androgen blockade, or chemotherapy. Progression-free survival (PFS) and overall survival (OS) were analyzed.
Results:
Systemic therapy showed better PFS than radiotherapy (3-year PFS 47.6% vs. 30.0%, p = 0.031) without OS difference. Trastuzumab plus docetaxel showed the highest response rate (75%) and enabled curative-intent treatment in all cases, with the best PFS (3-year 87.5%, p = 0.012).
Conclusions:
Given the retrospective design and limited sample size, these findings should be regarded as hypothesis-generating. An upfront trastuzumab-based therapy followed by curative-intent treatment may be a promising option for selected patients with HER2-positive unresectable SDC.
Insights
Upfront systemic therapy, particularly trastuzumab plus docetaxel, improved progression-free survival (PFS) for unresectable salivary duct carcinoma (SDC) compared to radiotherapy. This suggests a promising approach for HER2-positive SDC patients.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Optimal treatment for non-metastatic unresectable salivary duct carcinoma (SDC) is not well-defined.
- This study compares upfront biomarker-targeted systemic therapy with radiotherapy for SDC management.
Purpose of the Study:
- To compare the efficacy of upfront systemic therapy versus radiotherapy in patients with non-metastatic unresectable SDC.
- To evaluate progression-free survival (PFS) and overall survival (OS) based on initial treatment modality.
Main Methods:
- Retrospective analysis of 31 patients with centrally confirmed non-metastatic unresectable SDC.
- Patients were categorized by initial treatment: radiotherapy or systemic therapy (trastuzumab plus docetaxel, combined androgen blockade, or chemotherapy).
- Progression-free survival (PFS) and overall survival (OS) were analyzed.
Main Results:
- Systemic therapy demonstrated significantly better 3-year PFS (47.6%) compared to radiotherapy (30.0%, p=0.031).
- No significant difference in overall survival (OS) was observed between the groups.
- Trastuzumab plus docetaxel achieved the highest response rate (75%) and the best 3-year PFS (87.5%, p=0.012), enabling curative-intent treatment.
Conclusions:
- Findings suggest upfront systemic therapy, especially trastuzumab-based regimens, may improve PFS in unresectable SDC.
- Trastuzumab plus docetaxel shows promise for HER2-positive SDC, potentially allowing for curative-intent treatment.
- Given the retrospective nature and small sample size, results are hypothesis-generating and warrant further investigation.
